Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of CC220 (Iberdomide) Combined With Low-dose Cyclophosphamide and Dexamethasone in Relapsed/Refractory Multiple Myeloma (IberCd): ICON Study

NCT04392037 is registered in ClinicalTrials.gov with Amsterdam UMC, location VUmc as lead sponsor.

NCT NCT04392037
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04392037 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of CC220 (Iberdomide) Combined With Low-dose Cyclophosphamide and Dexamethasone in Relapsed/Refractory Multiple Myeloma (IberCd): ICON Study
Lead sponsor
Amsterdam UMC, location VUmc
Phase
Phase 2
Overall status
Active, not recruiting
Start date
February 17, 2021
Completion date
December 31, 2027
Enrollment
60 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma